Silver Spike Investment Corp. (NASDAQ: SSIC) Stock Competitors & Peer Comparison
See SSIC's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SSIC and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SSIC | $10.74 | +1.27% | 66.7M | 11.93 | $0.90 | N/A |
| TAK | $18.71 | +1.52% | 59.5B | 13.45 | $1.39 | +3.37% |
| HLN | $9.86 | -0.50% | 43.4B | 18.39 | $0.54 | +2.01% |
| TEVA | $36.62 | -2.32% | 42.6B | 12.50 | $2.93 | N/A |
| ZTS | $76.29 | +0.16% | 32B | 11.59 | $6.58 | +2.73% |
| VTRS | $16.94 | -0.88% | 19.7B | 6.72 | $2.52 | +2.83% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.42 | -1.05% | 12.2B | 23.03 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.03 | -1.11% | 10B | 19.73 | $0.61 | +0.70% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SSIC vs TAK Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TAK has a market cap of 59.5B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TAK trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TAK's P/E ratio is 13.45. In terms of profitability, SSIC's ROE is +0.00%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SSIC is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check TAK's competition here
Haleon plc (NYSE: HLN)
SSIC vs HLN Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while HLN trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas HLN's P/E ratio is 18.39. In terms of profitability, SSIC's ROE is +0.00%, compared to HLN's ROE of +0.17%. Regarding short-term risk, SSIC is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SSIC vs TEVA Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TEVA has a market cap of 42.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TEVA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TEVA's P/E ratio is 12.50. In terms of profitability, SSIC's ROE is +0.00%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, SSIC is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
SSIC vs ZTS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ZTS has a market cap of 32B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ZTS trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ZTS's P/E ratio is 11.59. In terms of profitability, SSIC's ROE is +0.00%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, SSIC is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
SSIC vs VTRS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while VTRS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas VTRS's P/E ratio is 6.72. In terms of profitability, SSIC's ROE is +0.00%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, SSIC is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SSIC vs ITCI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SSIC's ROE is +0.00%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SSIC is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SSIC vs ELAN Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ELAN trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ELAN's P/E ratio is 23.03. In terms of profitability, SSIC's ROE is +0.00%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, SSIC is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
SSIC vs CTLT Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SSIC's ROE is +0.00%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SSIC is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SSIC vs RDY Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, RDY has a market cap of 10B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while RDY trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas RDY's P/E ratio is 19.73. In terms of profitability, SSIC's ROE is +0.00%, compared to RDY's ROE of +0.09%. Regarding short-term risk, SSIC is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
SSIC vs ALKS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ALKS trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ALKS's P/E ratio is 49.35. In terms of profitability, SSIC's ROE is +0.00%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SSIC is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SSIC vs LNTH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while LNTH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas LNTH's P/E ratio is 16.97. In terms of profitability, SSIC's ROE is +0.00%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, SSIC is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SSIC vs AMRX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AMRX trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AMRX's P/E ratio is 19.86. In terms of profitability, SSIC's ROE is +0.00%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, SSIC is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SSIC vs INDV Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while INDV trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas INDV's P/E ratio is 9.54. In terms of profitability, SSIC's ROE is +0.00%, compared to INDV's ROE of -2.16%. Regarding short-term risk, SSIC is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SSIC vs RGC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas RGC's P/E ratio is -456.34. In terms of profitability, SSIC's ROE is +0.00%, compared to RGC's ROE of -2.32%. Regarding short-term risk, SSIC is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
SSIC vs ALVOW Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ALVOW's P/E ratio is 46.65. In terms of profitability, SSIC's ROE is +0.00%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, SSIC is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
SSIC vs SUPN Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SUPN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SUPN's P/E ratio is 14.38. In terms of profitability, SSIC's ROE is +0.00%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, SSIC is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SSIC vs BHC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas BHC's P/E ratio is 1.73. In terms of profitability, SSIC's ROE is +0.00%, compared to BHC's ROE of +0.89%. Regarding short-term risk, SSIC is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SSIC vs HCM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while HCM trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas HCM's P/E ratio is 5.29. In terms of profitability, SSIC's ROE is +0.00%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SSIC is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SSIC vs DCPH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SSIC's ROE is +0.00%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SSIC is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SSIC vs AVDL Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SSIC's ROE is +0.00%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, SSIC is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
SSIC vs TRLV Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TRLV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TRLV's P/E ratio is -4.88. In terms of profitability, SSIC's ROE is +0.00%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, SSIC is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
SSIC vs PRGO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PRGO trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PRGO's P/E ratio is 5.71. In terms of profitability, SSIC's ROE is +0.00%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, SSIC is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
SSIC vs EMBCV Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SSIC's ROE is +0.00%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SSIC is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SSIC vs DVAX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SSIC's ROE is +0.00%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, SSIC is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
SSIC vs ALVO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ALVO trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ALVO's P/E ratio is -15.82. In terms of profitability, SSIC's ROE is +0.00%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, SSIC is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SSIC vs ETON Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ETON trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ETON's P/E ratio is 130.22. In terms of profitability, SSIC's ROE is +0.00%, compared to ETON's ROE of +0.40%. Regarding short-term risk, SSIC is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SSIC vs ANIP Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ANIP trades at $71.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ANIP's P/E ratio is 8.76. In terms of profitability, SSIC's ROE is +0.00%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, SSIC is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SSIC vs TARO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TARO's P/E ratio is 30.05. In terms of profitability, SSIC's ROE is +0.00%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SSIC is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SSIC vs PAHC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PAHC trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PAHC's P/E ratio is 13.17. In terms of profitability, SSIC's ROE is +0.00%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, SSIC is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SSIC vs HROW Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while HROW trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas HROW's P/E ratio is -38.65. In terms of profitability, SSIC's ROE is +0.00%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SSIC is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
SSIC vs CRON Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CRON's P/E ratio is 30.96. In terms of profitability, SSIC's ROE is +0.00%, compared to CRON's ROE of +0.06%. Regarding short-term risk, SSIC is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SSIC vs AMPH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AMPH trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AMPH's P/E ratio is 8.14. In terms of profitability, SSIC's ROE is +0.00%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, SSIC is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SSIC vs PCRX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PCRX trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PCRX's P/E ratio is 10.23. In terms of profitability, SSIC's ROE is +0.00%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, SSIC is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SSIC vs PETQ Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SSIC's ROE is +0.00%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SSIC is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SSIC vs COLL Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, COLL has a market cap of 768.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while COLL trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas COLL's P/E ratio is 2.97. In terms of profitability, SSIC's ROE is +0.00%, compared to COLL's ROE of +0.16%. Regarding short-term risk, SSIC is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SSIC vs IRWD Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas IRWD's P/E ratio is 5.50. In terms of profitability, SSIC's ROE is +0.00%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, SSIC is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
SSIC vs EVO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, EVO has a market cap of 675M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas EVO's P/E ratio is -2.68. In terms of profitability, SSIC's ROE is +0.00%, compared to EVO's ROE of -0.27%. Regarding short-term risk, SSIC is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SSIC vs AQST Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AQST has a market cap of 671.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AQST trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AQST's P/E ratio is -8.23. In terms of profitability, SSIC's ROE is +0.00%, compared to AQST's ROE of +2.44%. Regarding short-term risk, SSIC is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check AQST's competition here
Glass House Brands Inc (NYSE: GLAS)
SSIC vs GLAS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, GLAS has a market cap of 662.8M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while GLAS trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas GLAS's P/E ratio is -15.30. In terms of profitability, SSIC's ROE is +0.00%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, SSIC is similarly volatile compared to GLAS. This indicates similar risk in terms of short-term price fluctuations for SSIC.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
SSIC vs EOLS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, EOLS has a market cap of 596M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while EOLS trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas EOLS's P/E ratio is -28.66. In terms of profitability, SSIC's ROE is +0.00%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, SSIC is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SSIC vs BDSI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SSIC's ROE is +0.00%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SSIC is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SSIC vs TLRY Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TLRY has a market cap of 506.6M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TLRY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TLRY's P/E ratio is -4.18. In terms of profitability, SSIC's ROE is +0.00%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, SSIC is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
SSIC vs KMDA Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, KMDA has a market cap of 477.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas KMDA's P/E ratio is 21.76. In terms of profitability, SSIC's ROE is +0.00%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SSIC is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SSIC vs CGC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CGC has a market cap of 410.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CGC's P/E ratio is -0.59. In terms of profitability, SSIC's ROE is +0.00%, compared to CGC's ROE of -0.33%. Regarding short-term risk, SSIC is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SSIC vs TKNO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TKNO has a market cap of 388.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TKNO trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TKNO's P/E ratio is -23.35. In terms of profitability, SSIC's ROE is +0.00%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SSIC is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
SSIC vs EBS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, EBS has a market cap of 322M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while EBS trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas EBS's P/E ratio is 4.33. In terms of profitability, SSIC's ROE is +0.00%, compared to EBS's ROE of -0.36%. Regarding short-term risk, SSIC is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SSIC vs ALIM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SSIC's ROE is +0.00%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SSIC is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
SSIC vs LNDC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SSIC's ROE is +0.00%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, SSIC is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check LNDC's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SSIC vs CRDL Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CRDL has a market cap of 249M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CRDL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CRDL's P/E ratio is -8.61. In terms of profitability, SSIC's ROE is +0.00%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, SSIC is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CRDL's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SSIC vs ACB Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ACB has a market cap of 241M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ACB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ACB's P/E ratio is -7.94. In terms of profitability, SSIC's ROE is +0.00%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SSIC is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SSIC vs SIGA Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SIGA has a market cap of 231.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SIGA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SIGA's P/E ratio is 11.96. In terms of profitability, SSIC's ROE is +0.00%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SSIC is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
SSIC vs TYHT Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SSIC's ROE is +0.00%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SSIC is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
SSIC vs DERM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, DERM has a market cap of 217.4M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while DERM trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas DERM's P/E ratio is -21.35. In terms of profitability, SSIC's ROE is +0.00%, compared to DERM's ROE of -0.20%. Regarding short-term risk, SSIC is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SSIC vs ORGO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ORGO has a market cap of 211M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ORGO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ORGO's P/E ratio is 54.67. In terms of profitability, SSIC's ROE is +0.00%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, SSIC is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SSIC vs REPH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas REPH's P/E ratio is -8.04. In terms of profitability, SSIC's ROE is +0.00%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SSIC is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
SSIC vs OGI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, OGI has a market cap of 164.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while OGI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas OGI's P/E ratio is 2.63. In terms of profitability, SSIC's ROE is +0.00%, compared to OGI's ROE of +0.21%. Regarding short-term risk, SSIC is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SSIC vs LFCR Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, LFCR has a market cap of 163.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while LFCR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas LFCR's P/E ratio is -4.07. In terms of profitability, SSIC's ROE is +0.00%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, SSIC is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SSIC vs THTX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas THTX's P/E ratio is -28.83. In terms of profitability, SSIC's ROE is +0.00%, compared to THTX's ROE of +0.36%. Regarding short-term risk, SSIC is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SSIC vs ASRT Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SSIC's ROE is +0.00%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SSIC is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SSIC vs SCTL Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SSIC's ROE is +0.00%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SSIC is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
SSIC vs BGM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, BGM has a market cap of 107.8M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas BGM's P/E ratio is -0.98. In terms of profitability, SSIC's ROE is +0.00%, compared to BGM's ROE of -0.05%. Regarding short-term risk, SSIC is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
SSIC vs PROC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PROC's P/E ratio is 1.53. In terms of profitability, SSIC's ROE is +0.00%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SSIC is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SSIC vs CPIX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CPIX's P/E ratio is -16.87. In terms of profitability, SSIC's ROE is +0.00%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SSIC is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SSIC vs OPTN Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SSIC's ROE is +0.00%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SSIC is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SSIC vs ZOM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SSIC's ROE is +0.00%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, SSIC is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SSIC vs GRVI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SSIC's ROE is +0.00%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, SSIC is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SSIC vs ZYBT Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, SSIC's ROE is +0.00%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, SSIC is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SSIC vs ZYNE Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SSIC's ROE is +0.00%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SSIC is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
SSIC vs INCR Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while INCR trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas INCR's P/E ratio is -12.23. In terms of profitability, SSIC's ROE is +0.00%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SSIC is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
SSIC vs TLPH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TLPH's P/E ratio is -3.87. In terms of profitability, SSIC's ROE is +0.00%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, SSIC is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SSIC vs VLNS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SSIC's ROE is +0.00%, compared to VLNS's ROE of N/A. Regarding short-term risk, SSIC is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
SSIC vs DRRX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SSIC's ROE is +0.00%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, SSIC is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SSIC vs JUPW Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SSIC's ROE is +0.00%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, SSIC is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SSIC vs QLI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas QLI's P/E ratio is -4.92. In terms of profitability, SSIC's ROE is +0.00%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SSIC is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SSIC vs CPHI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CPHI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CPHI's P/E ratio is -1.97. In terms of profitability, SSIC's ROE is +0.00%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, SSIC is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SSIC vs RMTI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while RMTI trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas RMTI's P/E ratio is -5.96. In terms of profitability, SSIC's ROE is +0.00%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, SSIC is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
SSIC vs HEXO Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SSIC's ROE is +0.00%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SSIC is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SSIC vs TXMD Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, TXMD has a market cap of 25.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while TXMD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas TXMD's P/E ratio is 114.11. In terms of profitability, SSIC's ROE is +0.00%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SSIC is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SSIC vs AYTU Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AYTU's P/E ratio is -1.19. In terms of profitability, SSIC's ROE is +0.00%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, SSIC is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SSIC vs CYTH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SSIC's ROE is +0.00%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SSIC is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SSIC vs EVOK Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SSIC's ROE is +0.00%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, SSIC is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SSIC vs OPTH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, OPTH has a market cap of 15.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while OPTH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas OPTH's P/E ratio is -17.24. In terms of profitability, SSIC's ROE is +0.00%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, SSIC is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SSIC vs ACRX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SSIC's ROE is +0.00%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, SSIC is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
SSIC vs CABR Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, CABR has a market cap of 11.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while CABR trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas CABR's P/E ratio is -2.29. In terms of profitability, SSIC's ROE is +0.00%, compared to CABR's ROE of -3.86%. Regarding short-term risk, SSIC is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SSIC vs AGRX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SSIC's ROE is +0.00%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SSIC is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SSIC vs NLTX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SSIC's ROE is +0.00%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SSIC is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check NLTX's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SSIC vs GELS Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, GELS has a market cap of 7.9M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while GELS trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas GELS's P/E ratio is -1.72. In terms of profitability, SSIC's ROE is +0.00%, compared to GELS's ROE of -0.25%. Regarding short-term risk, SSIC is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check GELS's competition here
Lannett Company, Inc. (NYSE: LCI)
SSIC vs LCI Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas LCI's P/E ratio is -0.04. In terms of profitability, SSIC's ROE is +0.00%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SSIC is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SSIC vs ADMP Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SSIC's ROE is +0.00%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SSIC is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
SSIC vs YCBD Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, YCBD has a market cap of 5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas YCBD's P/E ratio is -1.17. In terms of profitability, SSIC's ROE is +0.00%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SSIC is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
SSIC vs MNK Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas MNK's P/E ratio is -0.44. In terms of profitability, SSIC's ROE is +0.00%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SSIC is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SSIC vs FLGC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SSIC's ROE is +0.00%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SSIC is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
SSIC vs UPC Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while UPC trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas UPC's P/E ratio is -0.54. In terms of profitability, SSIC's ROE is +0.00%, compared to UPC's ROE of -0.03%. Regarding short-term risk, SSIC is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
SSIC vs SBFM Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SBFM has a market cap of 2.6M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SBFM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SBFM's P/E ratio is -0.18. In terms of profitability, SSIC's ROE is +0.00%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, SSIC is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SSIC vs PLXP Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SSIC's ROE is +0.00%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SSIC is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
SSIC vs ATNX Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SSIC's ROE is +0.00%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SSIC is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
SSIC vs RDHL Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas RDHL's P/E ratio is 0.14. In terms of profitability, SSIC's ROE is +0.00%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, SSIC is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SSIC vs SNOA Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SNOA's P/E ratio is -1.12. In terms of profitability, SSIC's ROE is +0.00%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SSIC is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for SSIC.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
SSIC vs SHPH Comparison September 2026
Silver Spike Investment Corp. (NASDAQ: SSIC) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SSIC stands at 66.7M. In comparison, SHPH has a market cap of 2M. Regarding current trading prices, SSIC is priced at $10.74 on the NASDAQ, while SHPH trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SSIC currently has a P/E ratio of 11.93, whereas SHPH's P/E ratio is -0.16. In terms of profitability, SSIC's ROE is +0.00%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, SSIC is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for SSIC.Check SHPH's competition here